logo

ISIS PHARM(NSDQ:ISIS)
Isis Pharmaceuticals, Inc. is a leading genomics-based drug discoveryand development company that is focused on RNA. RNA is a novel target for drug discovery, and Isis has established a dominant position in RNA research. The company has integrated the expertise in molecular and cellular biology, medicinal chemistry, RNA biochemistry, bioinformatics, pharmacology and clinical development to create two exciting technologies, antisense and Ibis, a robust pipeline of drugs in development and genomics services.
# Employees: 300
Address: 1896 Rutherford Road,Carlsbad,CA,USA
Phone: 760 931-9200
Fax: 760 603-2700
Website: www.isispharm.com
Email: info@isisph.com
Sector: Medical
Industry: MED-BIOMED/GENE
Executive Officers
Stanley T. Crooke Ph.D. (Chmn.; Pres.; C.E.O.)
Michael J. Treble M.D. (Sr.V.P.; Presi.; Ibis Biosciences; Inc.)
Frank C. Bennett Ph.D. (Sr.V.P.; Antisense Research)
David J. Ecker Ph.D. (Sr.V.P.; C.S.O. Ibis Biosciences; Inc.)
Lynne B. Parshall J.D. (C.F.O.; C.O.O.; Sec.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2009
Next Earnings Date(Expected): 2/24/2010
Mean EPS (Next Qtr): ($0.09)
Mean EPS (Year): ($0.14)
Mean Estimate(Long Term): $26.50
P/E Ratio(Based on EPS estimate): -0.010
Number of Estimates: 8
Shares Performance
Period ISIS Compare to S&P
YTD -20.80 % -34.46 %
4 Weeks -18.92 % -19.79 %
12 Weeks -30.46 % -34.44 %
Shares Information
Analyst Coverage: Y
Avg Volume: 2023171
Shares Outstanding: 98M
Market Cap: $1.10B
52 Week High: $18.70
52 Week Low: $10.37
P/E Ratio: -0.010
PEG Ratio: -0.010
Split: On 1/1/1990 ISIS split by factor of 2.000
Earnings Performance
EPS Growth in Last Quarter: -133.33 %
EPS Growth in Last Year: -333.33 %
Sales Growth in Last Quarter: -13.62 %
Sales Growth in Last Quarter: -16.90 %
Financials
Qtr Book Value: $3.62
Cash Flow/Share: $286.36
Change in Payout Ratio: -0.010
Price/Sales: 9.280
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia